Stand Up To Cancer - standuptocancer.orgThis is where the end of cancer begins
   Please leave this field empty

Endometrial Cancer Mismatch Repair Therapy Convergence Team

Share this:
Email

Like this page on Facebook

 

Responders and Non-responders to Endometrial Cancers with Mismatch Repair

Team Leader

  • Alessandro D. Santin, MD

    Team Leader
    Co-Chief in Gynecologic Oncology Division in the Department of Obstetrics & Gynecology at Yale University
    + Full Bio

About This Team’s Research

Researchers do not know why only about one-half of all patients with Mismatch Repair Deficient, MSI-high(h) metastatic/recurrent tumors respond to anti-PD1 treatment. The team will develop and validate a novel computational method to assess DNA damage and tumor mutational burden using next generation sequencing data. Once validated, the approach will be applied to an ongoing trial for patients with endometrial cancer treated with Pembrolizumab. The team hopes to be able to predict the patients who will have side effects to checkpoint therapies, predict antigens from T cell receptor sequences, and determine neoantigens that are expressed by tumor that are recognized by the immune system in an HLA-dependent fashion. Identification of the patients who will have side effects will allow for modification of treatment to mitigate the adverse effects.

Click here to see a full list of Dream Team members
Click here to see the press release announcement